Paris-based Sonio, an AI software that helps practitioners to secure prenatal screening and optimise prenatal diagnosis, announced on Tuesday, December 20, that it has raised €10M in a fresh round of funding.
The investment came from the European Innovation Council (EIC) Accelerator, a fund that supports European deeptech companies. For this cohort, 78 firms out of 1092 submitted proposals were chosen by the EIC Accelerator.
Sonio’s current funding amount includes €2.5M received via grant and €7.5M in equity investment. This investment comes in addition to a €5M the company had previously raised via Elaia, OneRagtime and Bpi France in June 2022.
Brief about Sonio
Founded in 2020 by Cecile Brosset and Remi Besson, Sonio claims to be the only SaaS platform that combines technological innovation, medical knowledge, and collective intelligence to enable healthcare providers to offer secure prenatal care.
In order to maximise prenatal screening and diagnosis, the company offers a special AI programme that combines the expertise of prenatal medicine practitioners with all kinds of medical, imaging, genetic, and environmental data.
Sonio has been developed by a collaboration of entrepreneurs, scientists, medical professionals, and IT specialists. It is currently being used by over 250 healthcare professionals.
Since its inception, Sonio has already brought 2 products to market:
- Sonio Diagnostics: created for expert diagnostic ultrasounds, was CE marked and found its first clients in record time.
- Sonio Pro: specifically designed to increase the security and efficiency of routine prenatal ultrasounds. It was launched in October and claims to have already won over consumers in Europe.
The company has also established several collaborations, including with Samsung France, one of the leading women’s health ultrasound manufacturers, and also with specialised distributors – Lifecell in India, Manager Systems in Brazil, and Dynamic Medicals in Nigeria.
Capital utilisation
Sonio says it will use the funds to accelerate the release of new features on the platform, such as embedded image recognition and genomics. The funds will also help the company boost its sales in Europe and India while simultaneously gaining momentum to enter the US market.
Rémi Besson, Chief Scientific Officer and co-founder of Sonio, says, “For us, this funding means more research, more clinical studies, more innovation, more patents filed in Europe and ultimately an improved quality of care for patients, wherever they are. We are eager to intensify our scientific partnerships with some of the best experts in Fetal Medicine and Artificial Intelligence.”
01
Not solo: How Xolo aims to help Dutch solopreneurs with its comprehensive business management platform